Design: Phase 3, randomised 2:1, double-blind, placebo-controlled, 48 weeks
Population: 258 adults with transfusion-dependent alpha- or beta-thalassaemia, 19 countries
Primary outcome: Transfusion reduction response (at least 50% and 2 units fewer over 12 weeks)
Effect: 30% vs 13%; adjusted difference 18 percentage points (95% CI 8-27)

ENERGIZE-T randomised 258 adults with transfusion-dependent alpha- or beta-thalassaemia in 19 countries, 2:1, to mitapivat 100 mg twice daily or placebo for 48 weeks. Mitapivat is an oral activator of red cell pyruvate kinase, which improves the energy supply of fragile red cells.

The primary endpoint was at least a 50% fall in units transfused, and at least two units fewer, in at least one 12-week period. It was met by 30% on mitapivat and 13% on placebo (adjusted difference 18 percentage points, 95% CI 8 to 27). Serious adverse events were 11% and 15%. Discontinuation for adverse events was 6% and 1%; headache, insomnia and diarrhoea were the commonest complaints.

Most patients still needed regular transfusion, so this is a reduction in burden rather than independence from it. Thalassaemia is common in India, and an oral option would matter here, but the drug's regulatory status for thalassaemia in India is unknown and its cost is likely to be high.

Expect about one in three adults with transfusion-dependent thalassaemia on mitapivat to cut transfused units by at least half in at least one 12-week period, against about one in eight on placebo.
Continue iron chelation; reducing transfusions does not remove existing iron overload.
Refer interested patients to a haematology centre rather than prescribing outside specialist care.
Check availability and approval in your country before discussing it as a current option.

Why it matters

Thalassaemia care has relied largely on transfusion and chelation, and an oral drug that eases that burden changes the conversation in haematology clinics.

The statistics, in plain English

An 18-point difference means about six patients would need treating for one extra patient to cut transfused units by at least half in a 12-week period. The confidence interval of 8 to 27 points is well clear of zero, so the benefit is unlikely to be chance, but its size could be modest.